Heartbeam, Inc. Warrant (BEATW)
Company News
HeartBeam Cuts Costs Awaits FDA Decision
HeartBeam reported Q2 2025 results, showing a 23% decrease in cash burn and maintaining progress towards FDA clearance for its 12-lead ECG synthesis software, targeting a pilot launch in Florida and Southern California's concierge medical practices.